European Journal of Chemistry 3 (3) (2012) 287-292



Journal homepage: www.eurjchem.com



Synthesis and studies of pyrazolo[3,4-*b*]piperidin-4-one derivatives

Hussain Ali Soleiman*, Ali Kamel Khalafallah and Hana'a Abd-Ellatif

Chemistry Department, Aswan Faculty of Science, South Valley University, Aswan, 81111, Egypt

*Corresponding author at: Chemistry Department, Aswan Faculty of Science, South Valley University, Aswan, 81111, Egypt. Tel.: +20.97.3480447; fax: +20.97.3480450. E-mail address: hsoleiman2001@yahoo.com (H.A. Soleiman).

ARTICLE INFORMATION

ABSTRACT

Received: 10 April 2012 Received in revised form: 01 July 2012 Accepted: 08 July 2012 Online: 30 September 2012 A series of isolated/fused of pyrazole, isoxazolo, pyrimidine, pyrimidine thione, spiro thiazolodine and spiro β -lactam derivatives incorporating to 4-acetyl-5-amino-3-methyl-1-phenyl-2-pyrazoline have been synthesized by different methods of chemical reactions. The structure assignments of these compounds, based on chemical and spectroscopic evidence were deduced from their IR, ¹H NMR, elemental analysis and mass spectrometry.

KEYWORDS

Pyrazole Isoxazolo Pyrimidine Spiro β-lactam Pyrimidine thione Spiro thiazolodine

1. Introduction

Mannich reaction is a versatile reaction and was studied used widely in the synthesis of biologically important molecules and natural products [1-5]. The reaction between benzaldehyde, aniline and cyclohexanone as a model reaction in water in the presence of various amounts of first generation dendrimer [6-14]. It was found that only 2 mol % of the catalyst was required to drive the reaction smoothly to completion. The scope of the dendrimer catalyzed Mannich reaction was extended to other aldehydes, ketones and anilines [15-25]. In a similar manner condensation between other substrates like 4acetyl-5-imino-3-methyl-1-phenyl-2-pyrazoline (1) also a short period of time with excellent yield and high purity and non more purification was required. As literature search, it has found that Mannich bases had antimicrobial activities [26,27] besides various activities. The pyrazole nucleus is present in a wide variety of biologically interesting compounds, which exhibit ant hyperglycemic, analgesic, anti-inflammatory, antipyretic, antibacterial, hypoglycemic, sedative - hypnotic activity [28-31]. Pyrazoles and their derivatives are widely used as pharmaceutical [32,33] and agrochemical agents [34] and consequently a large number of synthetic routes to pyrazoles has been reported [35-38]. However, there is still great interest in finding milder and more efficient methods to these valuable compounds. Amino pyrazole derivative and imino pyrazole derivative undergo various reactions, and as such are excellent and general starting materials for the development of the organic synthesis.

2. Experimental

All melting points are uncorrected. IR spectra were recorded on a Pye Unicam SP-1100 Spectrophotometer KBr disc ¹H NMR spectra were recorded on a Varian EM-390 90M Hz spectrophotometer using DMSO d_6 as a solvent and TMS as an internal standard chemical shifts are expressed as ppm

units. The microanalysis was performed by the micro analytical centers at Cairo University. Mass spectra were obtained on a Shimadzu GCMS QP 1000 EX mass spectrometer at 70 eV.

2.1. Synthesis of 4-acetyl-5-imino-3-methyl-1-phenyl-2pyrazoline (1)

The compound (1) was carried out according to Mohanty *et al.*, 1977 [39].

2.2. Synthesis of 4-acetyl-5-amino-3-methyl-1-phenyl-2pyrazoline (2)

The compound **1** (2 g, 0.004 mol) was dissolved in 20 mL acetic acid with 1 g zinc dust, reflux for 2-3 hr. The hot mixture was filtrated to get off zinc dust residue. The filtrate was poured on ice/water with continuous stirring. The solid product was collected by filtration and crystallized from the diluted acetic acid (Scheme 1, Tables 1, 2).

2.3. Synthesis of 3-methyl-1-phenyl-5,6,7,7a-tetrahydro-1Hpyrazolo[3,4-b]pyridin-4(3aH)-one (3)

A solution of compound **2** (1.78 g, 0.008 mol) in dimethyl formamide was treated with paraformaldehyde (0.25 g, 0.008 mol) and piperidine (0.82 mL, 0.009 mol) and HCl (0.41 mL, 0.01 mol). The reaction mixture was heated under reflux for 3 hr, then left to cool and was poured into ice/water with the stirring. The solid product so formed was collected by filtration and crystallized from the diluted DMF (Scheme 1, Tables 1, 2).

2.4. Synthesis of 5-benzylidene-3-methyl-1-phenyl-5,6,7,7atetrahydro-1H-pyrazolo[3,4-b]pyridin-4(3aH)-one (4a), 5-(4-methoxybenzylidene)-3-methyl-1-phenyl-5,6,7,7atetrahydro-1H-pyrazolo[3,4-b]pyridin-4(3aH)-one (4b), 5-(4-hydroxybenzylidene)-3-methyl-1-phenyl-5,6,7,7atetrahydro-1H-pyrazolo[3,4-b]pyridin-4(3aH)-one (4c)

European Journal of Chemistry ISSN 2153-2249 (Print) / ISSN 2153-2257 (Online) © 2012 EURJCHEM DOI:10.5155/eurjchem.3.3.287-292.611



Scheme 1

A solution of compound **3** (1.17 g, 0.005 mol) was treated with aromatic aldehyde compounds (**4a**: 0.54 mL, 0.005 mol; **4b**: 0.68 mL, 0.005 mol; **4c**: 0.61 g, 0.005 mol) in the presence of 3 drops piperidine as a catalyst. The reaction mixture was heated under reflux for 4 hr, then left to cool and was poured on ice/water with stirring. The solid product so formed was collected by filtration and crystallized from the diluted DMF (Scheme 1, Tables 1, 2).

2.5. Synthesis of 1-(8-methyl-3,6-diphenyl-3,3a,4,5,5a,6hexahydrodipyrazolo[3,4-b:3',4'-d]pyridin-2(8aH)-yl) ethanone (5a), 1-(3-(4-methoxyphenyl)-8-methyl-6-phenyl-3,3a,4,5,5a,6-hexahydrodipyrazolo[3,4-b:3',4'-d] pyridin-2

(8aH)-yl)ethanone (5b), 1-(3-(4-hydroxyphenyl)-8-methyl-6phenyl-3,3a,4,5,5a,6-hexahydrodipyrazolo[3,4-b:3',4'-d] pyridin-2(8aH)-yl)ethanone (5c)

A solution of compounds **4a-c** (**4a**: 0.31 g, 0.001 mol; **4b**: 0.34 g, 0.001 mol; **4c**: 0.33 g, 0.001 mol) in dimethyl formamide was treated with hydrazine monohydrate (0.05 mL, 0.001 mol) in the presence of 4 drops of acetic acid. The reaction mixture was heated under reflux for 8 hr, then left to cool and was poured on ice/water. The solid product so formed was collected by filtration and crystallized from the diluted DMF (Scheme 1, Tables 1, 2).

Comp. No.	Yield, %	M.P., °C	Color	Mol. Formula, (M.wt., g)	Elemental Analysis, % Calculated (Found)			Mass,
					С	Н	N	— m/z
3	66	208-210	Light yellow	C13H15N3O	68.12	6.55	18.3	228
				(229.28)	(68.15)	(6.57)	(18.5)	
4a	59	166-168	Greenish yellow	C20H19N3O	75.70	5.99	13.24	315
				(317.39)	(75.72)	(6.00)	(13.25)	
4b	98	130-132	Latency	$C_{21}H_{21}N_{3}O_{2}$	72.62	6.05	12.10	346
		100 110		(347.42)	(72.64)	(6.06)	(12.12)	
4c	92	138-140	Light beige	$C_{20}H_{19}N_{3}O_{2}$	72.07	5.70	12.61	331
F .	0.2	140 140	Duran	(333.39)	(/2.08)	(5.80)	(12.62)	274
5a	83	140-142	Brown	$C_{22}H_{23}N_5U$	(70.77)	0.10 ((15)	18.76	3/4
Гh	(1	150 160	Dault huorum	(3/3.46) C U N O	(70.76)	(6.15)	(18.76)	404
50	01	150-100-	Dark brown	(402 49)	(69.47)	0.20	17.30 (17.2E)	404
F -	75	160 162	Light brown	(403.46) CHN-O-	(00.47)	(0.10) E 01	(17.33)	200
30	75	100-102-	Light brown	(389.46)	(67.84)	(5.91	(17.97)	390
60	50	166 160	Proven	(309.40)	76.65	(3.90)	17.10	409
0a	50	100-100	BIOWII	(407 52)	(76.66)	(6.15)	(17.20)	400
6h	70	100-102	Brown	(407.52)	74.82	5 21	16.16	433
00	79	190-192	BIOWII	(422 51)	(74.02	(5.31	(16.17)	455
60	40	144-146	Dark hoigo	(455.51) CacHarNrO	72 75	5.01	1654	423
00	40	144-140	Darkbeige	(422 52)	(72.75)	(E 90)	(16 52)	425
75	Q1	154-156	Light orango	(423.52) CHN-O	72.28	6.02	21.08	346
7 a	01	154-150	Light of ange	(346.41)	(72.20)	(6.02)	(21.00	540
7h	66	100-102	Poddich brown	(340.41)	69.61	6.07	15.46	362
70	00	100-102	Reduisii bi own	(362.43)	(69.60)	(6.06)	(15.45)	302
7c	70	120-122	Dark beige	CaoHaoN (Oa	68.96	5 74	16.09	349
70	70	120-122	Darkbeige	(348.40)	(68.95)	(5.74)	(16.09)	349
89	50	225-227	Reddish brown	(340.40) CatHatNrO	70.78	5.84	19.49	357
0a	50	225-227	Reduisii bi own	(359.43)	(70.77)	(5.83)	(19.48)	557
8h	84	150-152	Reddish brown	(33).43) CaaHaaNrOa	67.86	5 90	17.99	389
05	01	150 152	itedulish brown	(389.46)	(67.84)	(5.70)	(17.99)	507
8c	50	139-140	Dark beige	C21H21NEO2	67.20	5.60	18.66	375
	00	107 110	Duritbeige	(375 43)	(66.20)	(5.50)	(18.66)	010
9a	40	176-178	brown	C21H21N5S	67.20	5.60	18.66	374
Ju	10	1/0 1/0	brown	(375.49)	(67.20)	(5.70)	(18.67)	071
9b	80	141-143	Beige	C22H23N5OS	65.16	5.72	17.27	405
			8-	(405.52)	(65.00)	(5.70)	(17.50)	
9c	38	139-140	Yellow	C21H21N5OS	64.45	5.37	17.90	391
				(391.49)	(64.43)	(5.35)	(17.90)	
10a	98	163-165	Beige	C21H23N5O	69.80	6.37	19.39	360
				(361.45)	(70.00)	(6.40)	(19.40)	
10b	40	168-170	Brown	C19H18N4O2	68.26	5.38	16.76	334
				(334.38)	(68.27)	(5.39)	(16.77)	
10c	98	149-151	Brown	$C_{23}H_{20}N_4O_2$	71.87	5.20	14.58	384
				(384.44)	(71.88)	(5.21)	(14.59)	
11a	20	150-152	Brown	C23H25N5O2S	63.44	5.74	16.09	435
				(435.54)	(63.45)	(5.75)	(16.09)	
11b	30	120-122	Brown	C21H20N4O3S	61.76	4.90	13.72	406
				(408.47)	(61.78)	(4.93)	(13.73)	
11c	25	125-127	Light brown	C25H22N4O3S	65.50	4.80	12.22	458
				(458.53)	(65.52)	(4.82)	(12.23)	
12a	15	145-146	Brown	C23H24N5O2Cl	63.15	5.49	16.01	436
				(437.93)	(63.16)	(5.50)	(16.03)	
12b	18	200-202	Brown	C21H19N4O3Cl	61.46	4.63	13.60	412
				(410.86)	(61.48)	(4.65)	(13.90)	
12c	10	145-147	Brown	C25H21N4O3Cl	65.21	4.56	12.17	460
				(460.92)	(65.22)	(4.57)	(12.18)	

Table 1. Characterization of compounds (3-12).

2.6. Synthesis of 8-methyl-2,3,6-triphenyl-2,3,3a,4,5,5a,6,8aoctahydrodipyrazolo[3,4-b:3',4'-d]pyridine (6a), 3-(4-methoxyphenyl)-8-methyl-2,6-diphenyl-2,3,3a,4,5,5a,6, 8a-octahydrodipyrazolo[3,4-b:3',4'-d] pyridine (6b), 3-(4hydroxyphenyl)-8-methyl-2,6-diphenyl-2,3,3a,4,5,5a,6,8aoctahydrodipyrazolo[3,4-b:3',4'-d] pyridine (6c)

A solution of compounds **4a-c** (**4a**: 0.31 g, 0.001 mol; **4b**: 0.34 g, 0.001 mol; **4c**: 0.33 g, 0.001 mol) in dimethyl formamide was treated with phenyl hydrazine (0.1 mL, 0.001 mol) in the presence of piperidine as catalyst. The reaction mixture was heated under reflux for 8 hr, then left to cool and was poured on ice/water. The solid product so formed was collected by filtration and crystallized from the diluted DMF (Scheme 1, Tables 1, 2).

2.7. Synthesis of 8-methyl-3,6-diphenyl-3a,4,5,5a,6,8ahexahydro-3H-isoxazolo[3,4-d]pyrazolo[3,4-b]pyridine (7a), 3-(4-methoxyphenyl)-8-methyl-6-phenyl-3a,4,5,5a,6,8ahexahydro-3H-isoxazolo[3,4-d]pyrazolo[3,4-b]pyridine (7b), 3-(4-hydroxyphenyl)-8-methyl-6-phenyl-3a,4,5,5a,6,8ahexahydro-3H-isoxazolo[3,4-d]pyrazolo[3,4-b]pyridine (7c)

A solution of compounds **4a-c** (**4a**: 0.31 g, 0.001 mol; **4b**: 0.34 g, 0.001 mol; **4c**: 0.33 g, 0.001 mol) in dimethyl formamide was treated with hydroxyl amine hydrochloride (0.1 g, 0.001 mol) in the presence of sodium hydroxide as a catalyst. The reaction mixture was heated under reflux for 8 hr, then left to cool and was poured on ice/water. The solid product so formed was collected by filtration and crystallized from the diluted DMF (Scheme 1, Tables 1, 2).

Comp. No	IR (cm ⁻¹)	¹ Η NMR (δ, ppm)
3	3063 (NH), 1706 (C=O), 1596 (C=N)	0.86 (s, 3H, CH ₃), 1.24 (d, <i>J</i> = 7.00 Hz, 1H, NCHN), 2.16 (t, <i>J</i> = 7.30 Hz, 2H, CH ₂ CO), 2.35 (d, <i>J</i> = 7.00, 1H, CHCO), 2.73 (t, <i>J</i> = 7.30 Hz, 2H, CH ₂ N), 3.37 (s, 1H, NH), 7.24-7.97 (m, 5H, Ar-H*)
4c	3392 (OH), 3068-3063 (NH), 1640-1623 (C=O)	0.79 (s, 3H, CH ₃), 1.23 (s, 1H, CHPh), 2.16 (d, <i>J</i> = 7.00 Hz, 1H, NCHN), 2.34 (d, <i>J</i> = 7.00 Hz, 1H, CHCO), 3.73 (s, 2H, CH ₂ N), 8.65 (s, 1H, NH), 6.7-8.1 (m, 9H, Ar-H ⁺), 9.8 (s, 1H, OH)
6c	3411-3150 (OH), 3064 (NH), 1707 (C=O), 1598 (C=N)	0.78 (s, 3H, CH ₃), 2.3 (s, 1H, NH), 6.7-8.0 (m, 20H, Ar-H+ + Heterocycle nuclei), 7.98 (s, 1H, OH)
7a	3064-3061 (NH), 1599-1598 (C=N)	0.77 (s, 3H, CH ₃), 3.34 (s, 1H, NH), 7.42-7.82 (m, 16H, Ar-H* + Heterocycle nuclei)
7b	3391-3150 (NH), 1598 (C=N)	0.78 (s, 3H, CH ₃), 2.14 (s, 1H, NH), 3.84 (s, 3H, OCH ₃), 6.5-8.0 (m, 15H, Ar-H ⁺ + Heterocycle nuclei)
8b	3062 (NH), 1706 (C=O), 1601-1599 (C=N)	0.78 (s, 3H, CH ₃), 1.17 (d, <i>J</i> = 7.00 Hz, 2H, NCHNH), 2.14 (q, <i>J</i> = 7.30 Hz, 1H, CHCH), 2.33 (d, <i>J</i> = 7.00 Hz, 1H, CHCN), 2.74 (d, <i>J</i> = 7.00, 1H, CHN), 2.9 (s, 2H, NH), 3.35 (s, 3H, OCH ₃), 3.69 (t, <i>J</i> = 7.30 Hz, 2H, CH ₂ N), 7.16-7.96 (m, 9H Ar-H ⁺)
8c	3416-3150 (OH, NH), 1708 (C=O), 1598 (C=N)	0.78 (s, 3H, CH ₃), 3.93 (s, 2H, NH), 6.0-7.97 (m, 16H, Ar-H+ + Heterocycle nuclei)
9a	3061 (NH), 1599 (C=N)	0.78 (s, 3H, CH ₃), 1.18 (q, <i>J</i> = 7.30 Hz, 1H, CHCH), 2.13 (d, <i>J</i> = 7.00 Hz, 1H, NCHN), 2.33 (d, <i>J</i> = 7.00 Hz, 1H, CHCN), 2.7 (d, <i>J</i> = 7.00 Hz, 1H, CHN), 2.9 (d, 2H, CH ₂ N), 3.31 (s, 2H, NH), 7.42-7.98 (m, 10H, Ar-H*)
9b	3391-3150 (OH), 3068 (NH), 1597 (C=N)	0.75 (s, 3H, CH ₃), 1.18 (q, <i>J</i> = 7.30 Hz, 1H, CHCH), 2.14 (d, <i>J</i> = 7.00 Hz, 1H, NCHN), 2.35 (d, <i>J</i> = 7.00 Hz, 1H, CHN), 2.68 (d, <i>J</i> = 7.00 Hz, 2H, CH ₂ N), 3.31 (br, 1H, NH), 3.33 (br, 1H, NHCS), 3.35 (s, 3H, OCH ₃), 7.18-7.97 (m, 10H, Ar-H ⁺ + Heterocycle nuclei)
10c	3425-3150 (NH, OH), 1625-1614 (C=N)	0.75 (s, 3H, CH ₃), 1.17 (d, <i>J</i> = 7.00 Hz, 1H, NCHN), 2.38 (d, <i>J</i> = 7.00 Hz, 1H, CHCO), 2.89 (s, 2H, CH ₂ N), 3.36 (s, 1H, NH), 6.89-7.48 (m, 11H, Ar-H ⁺), 7.96 (s, 1H, OH)
11b	3414-3150 (NH, OH), 1706 (C=O), 1601-1598 (C=N)	0.76 (s, 3H, CH ₃), 3.35 (s, 1H, NH), 6.0-7.8 (m, 15H, Ar-H+ + Heterocycle nuclei), 7.96 (s, 1H, OH)
11c	3411-3150 (OH), 3064-3061 (NH), 1751-1710 (C=O)	1.17 (s, 3H, CH ₃), 3.34 (s, 1H, NH), 6.0-7.6 (m, 17H, Ar-H ⁺ + Heterocycle nuclei), 7.82 (s, 1H, OH)
12c	3428-3061 (NH), 1709-1706 (C=O)	0.78 (s, 3H, CH ₃), 1.17 (d, <i>J</i> = 7.00 Hz, 1H, NCHN), 1.19 (d, <i>J</i> = 7.00 Hz, 1H, CHCO), 2.15 (s, 2H, CH ₂ N), 2.36 (s, 1H, NH), 3.38 (s, 1H, CHCI), 7.10-7.48 (m, 11H, Ar-H ⁺), 7.87 (s, 1H, OH)

Table 2. IR, ¹H NMR spectral data of compound (3-12).

2.8. Synthesis of 9-methyl-4,7-diphenyl-3,4,4a,5,6,6a,7,9aoctahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2one (8a), 4-(4-methoxyphenyl)-9-methyl-7-phenyl-3,4,4a, 5,6,6a,7,9a-octahydro-2H-pyrazolo[4',3':5,6] pyrido[4,3-d] pyrimidin-2-one (8b), 4-(4-hydroxyphenyl)-9-methyl-7phenyl-3,4,4a,5,6,6a,7,9a-octahydro-2H-pyrazolo[4',3':5,6] pyrido[4,3-d]pyrimidin-2-one (8c)

A solution of compounds **4a-c** (**4a**: 0.31 g, 0.001 mol; **4b**: 0.34 g, 0.001 mol; **4c**: 0.33 g, 0.001 mol) in dimethyl formamide was treated with urea (0.06 g, 0.001 mol) in the presence of sodium hydroxide as a catalyst. The reaction mixture was heated under reflux for 8 hr, then left to cool and was poured on ice/water. The solid product so formed was collected by filtration and crystallized from the diluted DMF (Scheme 1, Tables 1, 2).

2.9. Synthesis of 9-methyl-4,7-diphenyl-3,4,4a,5,6,6a,7,9aoctahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidine-2thione (9a), 4-(4-methoxyphenyl)-9-methyl-7-phenyl-3,4,4a, 5,6,6a,7,9a-octahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d] pyrimidine-2-thione (9b), 4-(4-hydroxyphenyl)-9-methyl-7phenyl-3,4,4a,5,6,6a,7,9a-octahydro-2H-pyrazolo[4',3':5,6] pyrido[4,3-d]pyrimidine-2-thione (9c)

A solution of compounds **4a-c** (**4a**: 0.31 g, 0.001 mol; **4b**: 0.34 g, 0.001 mol; **4c**: 0.33 g, 0.001 mol) in dimethyl formamide was treated with thiourea (0.076 g, 0.001 mol) in the presence of sodium hydroxide as a catalyst. The reaction mixture was heated under reflux for 8 hr, then left to cool and was poured on ice/water. The solid product so formed was collected by filtration and crystallized from the diluted DMF (Scheme 1, Tables 1, 2).

2.10. Synthesis of 5-((4-(dimethylamino)phenyl)imino)-3methyl-1-phenyl-5,6,7,7a-tetrahydro-1H-pyrazolo[3,4-b] pyridin-4(3aH)-one (10a), 5-((4-hydroxyphenyl)imino)-3methyl-1-phenyl-5,6,7,7a-tetrahydro-1H-pyrazolo[3,4-b] pyridin-4(3aH)-one (10b), 5-((2-hydroxynaphthalen-1-yl) imino)-3-methyl-1-phenyl-5,6,7,7a-tetrahydro-1H-pyrazolo [3,4-b]pyridin-4(3aH)-one (10c)

A solution of compound **3** (0.5 g, 0.002 mol) in dimethyl formamide was treated with nitroso compounds (**10a**: 0.32 mL, 0.002 mol; **10b**: 0.24 g, 0.002 mol; **10c**: 0.34 mL, 0.002 mol) in presence of 2 drops of piperidine as a catalyst. The reaction mixture was heated under reflux for 8-10 hr, then left to cool and was poured on ice/water. The solid product so formed was collected by filtration and crystallized from the diluted DMF (Scheme 2, Tables 1, 2).

2.11. Synthesis of 3'-(4-(dimethylamino)phenyl)-3-methyl-1phenyl-1,6,7,7a-tetrahydrospiro[pyrazolo[3,4-b]pyridine-5,2'-thiazolidine]-4,4'(3aH)-dione (11a), 3'-(4-hydroxy phenyl)-3-methyl-1-phenyl-1,6,7,7a-tetrahydrospiro [pyrazolo[3,4-b]pyridine-5,2'-thiazolidine]-4,4'(3aH)-dione (11b), 3'-(2-hydroxynaphthalen-1-yl)-3-methyl-1-phenyl-1,6,7,7a-tetrahydrospiro[pyrazolo[3,4-b]pyridine-5,2'thiazolidine]-4,4'(3aH)-dione (11c)

A solution of compounds **10a-c** (**10a**: 0.73 g, 0.002 mol; **10b**: 0.66 g, 0.002 mol; **10c**: 0.77 g, 0.002 mol) in dimethyl formamide was treated with thioglycolic acid (0.18 mL, 0.002 mol) in presence of 2 drops of piperidine as a catalyst. The reaction mixture was heated under reflux for 8-10 hr, then left to cool and was poured on ice/water. The solid product so formed was collected by filtration and crystallized from the diluted DMF (Scheme 2, Tables 1, 2).





2.12. Synthesis of 3-chloro-1-(4-(dimethylamino)phenyl)-3'methyl-1'-phenyl-1',6',7',7a'-tetrahydrospiro[azetidine-2,5'pyrazolo[3,4-b]pyridine]-4,4'(3a'H)-dione (12a), 3-chloro-1-(4-hydroxyphenyl)-3'-methyl-1'-phenyl-1',6',7',7a'tetrahydrospiro[azetidine-2,5'-pyrazolo[3,4-b]pyridine]-4,4' (3a'H)-dione (12b), 3-chloro-1-(2-hydroxynaphthalen-1-yl)-3'-methyl-1'-phenyl-1',6',7',7a'-tetrahydrospiro [azetidine-2,5'-pyrazolo[3,4-b]pyridine]-4,4'(3a'H)-dione (12c)

A solution of compounds **10a-c** (**10a**: 0.73 g, 0.002 mol; **10b**: 0.66 g, 0.002 mol; **10c**: 0.77 g, 0.002 mol) in dimethyl formamide was treated with chloroacetylchloride (0.23 mL, 0.002 mol) in presence of 2 drops of triethylamine as a catalyst. The reaction mixture was heated under reflux for 8-10 hr, then left to cool and was poured on ice/water. The solid product so formed was collected by filtration and crystallized from the diluted DMF Scheme 2, (Tables 1, 2).

3. Results and discussion

By using 4-acetyl-5-imino-3-methyl-1-phenyl-2-pyrazoline (1) [38], we could synthesize the new compound 4-acetyl-5-amino-3-methyl-1-phenyl-2-pyrazoline (2), Scheme 1 which has been considered as starting material for the synthesis of all newly compounds involved in this our research project. The structure of compound 2 was confirmed by IR spectra which revealed the presence of peaks at 3350 cm⁻¹ (NH₂), at 1670 cm⁻¹ (C=O), at 1600 cm⁻¹ (C=N), also ¹H NMR spectra of compound 2 revealed the presence of signals peaks at 1.4 (s, 3H, CH₃), 2.25 (s, 3H, CH₃CO), 2.65 (s, 1H, CHN), 2.85(s, 1H, CHCO), 4.20 (br, 2NH, NH₂), and 7.00-8.00 (m, 5H, Ar-H⁺) ppm, the mass spectrum showed the molecular ion peak at m/z = 229.28.

The structure of compound **3** was confirmed by IR spectra which revealed the presence of peaks at 3063 (NH), 1706 (C=O), 1596 (C=N) cm⁻¹, also ¹H NMR spectra of compound **3** revealed the presence of signals peaks at 0.86 (s, 3H, CH₃), 1.24 (d, *J* = 7.00 Hz, 1H, NCHN), 2.16 (t, *J* = 7.30 Hz, 2H, CH₂O), 2.35 (d, *J* = 7.00 Hz, H, CHCO), 2.73 (t, *J* = 7.30 Hz, 2H, CH₂N), 3.37 (s,

1H, NH), and 7.24-7.97 (m, 5H, Ar-H⁺) ppm and the mass spectra showed the molecular ion peak at m/z 228.

The active methylene group in compound **3** condensed with different aromatic aldehydes (benzaldehyde, anisaldehyde and *p*-hydroxybenzaldehyde) in dimethylformamide under piperidine as catalyst to yield the corresponding 5-aryldino-4-piperidinone derivatives (**4a-c**), respectively (Scheme 1). The structure of compounds **4a-c** was confirmed by IR spectrum, ¹H NMR spectrum and mass spectra (Tables 1, 2). The activity of exocyclic C=C conjugated with the *α*-carbonyl group in compounds **4a-c** were determined by the reaction with hydrazines, hydroxylamine hydrochloride, urea and thiourea, to yield the compounds **5-9a-c**, (Scheme 1). The isoxazolo piperidino derivatives (**7a** and **7b**), the piperidine derivatives (**8b, c**) and the pyrimidine thione derivatives (**9a, 9c**) were confirmed by micro-analytical and spectroscopic data.

The compounds (**10a-c**) were prepared by the condensation of 3-methyl-1-phenyl-5,6,7,7a-tetrahydro-1*H*-pyrazolo[3,4-*b*]pyridin-4(3*aH*)-one (**3**) with nitroso compounds such as (a) *p*-nitroso *N*,*N*-dimethyl aniline, (b) *p*-nitroso phenyl and (c) α -nitroso- β -naphthol in the presence of dimethylformamide as solvent under piperidine as catalyst (Scheme 2). When Schiff's base compounds (**10a-c**) reacted with thioglycolic acid in dimethylformamide under piperidine as catalyst yielded the corresponding *N*-thiazole derivatives (**11a-c**), (Scheme 2). By the reaction of Schiff's base compounds (**10a-c**) with chloroacetylchloride in dimethylformamide under triethylamine as catalyst yielded the corresponding *N*- β -lactam derivatives (**12a-c**) (Scheme 2).

4. Conclusion

The present study deals with the development of some synthetic applications of 3-methyl-1-phenyl-5-pyrazolone and is based on the generation of building blocks containing fused isolated and spiro heterocyclic compounds.

References

- [1]. Heaney, H. In Comprehensive Organic Synthesis; Trost, B. M., Fleming, I. Eds.; Pergamon Press: New York, 1991; Vol. 2, pp. 953-973.
- [2]. Arend, M.; Westermann, B.; Risch, N. Angew. Chem., Int. Ed. 1998, 37, 1044-1070.
- [3]. Denmark, S. E.; Nicaise, O. J. C. In Comprehensive Asymmetric Catalysis; Jacobsen, E. N.; Pfaltz, A.; Yamamoto, H. Springer, Heidelberg, 1999, Vol. 2, pp. 923-964.
- [4]. Kobayashi, S.; Ishitani, H. Chem. Rev. 1999, 99, 1069-1094.
- [5]. Cordova, A. Acc. Chem. Res. **2004**, 93, 522-528.
- [6]. Newkome, G. R.; Moorefield, C. N.; Vogtle, F. Dendrimers and Dendrons; Wiley-VCH: Verlag GmbH, 2002.
 [7]. Dendrimers and Other Dendritic Polymers; Frechet, J. M. J.; Tomalia, D.
- A., Eds.; John Wiley & Sons: Chichester, 2001.
 [8]. Dendrimers in Catalysis; Topics in Organometallic Chemistry; Gade,
- L. H., Eds.; Springer-Verlag: Heidelberg, 2006; Vol. 20, 1-42.
 Mery, D.; Astruc, D. Coord. Chem. Rev. 2006, 250(15-16), 1965-1979.
- [19]. Helms, B.; Frechet, J. M. J. Adv. Synth. Catal. 2006, 348, 1125-1148
- [11] Astruc, D.; Heuze, K.; Gatard, S.; Mery, D.; Nlate, S.; Plault, L. Adv. Synth. Catal. 2005, 347, 329-338.
- [12]. Astruc, D.; Chardac, F. Chem. Rev. 2001, 101, 2991-3023.
- [13]. Ooosterom, G. E.; Reek, J. N. H.; Kamer, P. C. J.; VanLeeuwen, P. W. N. M. Angew. Chem. Int. Ed. 2001, 40, 1828-1849.
- [14]. Scot, R. W. J.; Wilson, O. M.; Crooks, R. M. J. Phys. Chem. B. 2005, 109, 692-704.
- [15]. Wu, H.; Chen, X.; Wan, Y.; Ye, L.; Xin, H.; Xu, H.; Yue, C.; Pang, L.; Ma, R. Shi, D. Tetrahedron Lett. 2009, 50, 1062-1065.
- [16]. Dziedzic, V.; Ibrahem, I.; Cordova, A. Tetrahedron Lett. 2008, 49, 803-807.
- [17]. Hayashi, Y.; Urushima, T.; Aratake, S.; Okano, T.; Obi, K. Org. Lett. 2008, 10(1), 21-24.
- [18]. Khan, A. T.; Pravin, T.; Choudhary, L. H. Eur. J. Org. Chem. 2008, 834-839.
- [19]. Bigdeli, M. A.; Nemati, F.; Mahdavinia, G. H. Tetrahedron Lett. 2007, 48, 6801-6804.
- [20]. Guo, Q. X.; Liu, H.; Guo, C.; Luo, S. W.; Gu, Y.; Gong, L. Z. J. Am. Chem. Soc. 2007, 129, 3790-3791.
- [21]. Wang, R.; Li, B. G.; Huang, T. K.; Shi, L.; Lu, X. X. Tetrahedron Lett. 2007, 48, 2071-2073.
- [22]. Wu, H.; Shen, L. Y.; Fan, Y.; Zhang, P.; Chen, C. F.; Wang, W. X.

Tetrahedron 2007, 63, 2404-2408.

- [23]. Cheng, L.; Wu, X.; Lu, Y. Org. Biomol. Chem. 2007, 5, 1018-1020.
- [24]. Azizi, N.; Torkiyan, L.; Saidi, M. R. Org. Lett. 2006, 8, 2079-2082.
- [25]. Hayashi, Y.; Tsuboi, W.; Shoji, M.; Suzuki, N. J. Am. Chem. Soc. 2003, 125, 11208-11209.
- [26]. Tomalia, D. A. In Polymer Chemistry A Practical Approach: Davis, F. J. Eds.; Oxford University Press: UK, 2004; pp. 188-194.
- [27]. Tomalia, D. A.; Baker, H.; Dewald, J.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. Polym. J. 1985, 17, 117-132.
- [28]. Lee, K. Y; Kim, J. M.; Kim, J. N. *Tetrahedron Lett.* 2003, *44*, 6737-6740.
 [29]. LeBlanc, R.; Dickson, J.; Brown, T.; Stewart, M.; Pati, H. N.; VanDerveer, D.; Arman, H.; Harris, J.; Pennington, W.; Holt, H. L. Jr.; Lee, M. *Bioorg. Med. Chem.* 2005, *13*, 6025-6034.
- [30]. Bhat, B. A.; Dhar, K. L.; Puri, S. C.; Saxena, A. K.; Shanmugavel, M.; Qazi, G. N. Bioorg. Med. Chem. Lett. 2005, 15, 3177-3180.
- [31]. Bhat, B. A.; Puri, S. C.; Qurishi, M. A.; Dhar, K. L.; Qazi, G. N. Synth. Commun. 2005, 35, 1135-1142.
- [32]. Abdon, I. M.; Saleh, A. M.; Zodhi, H. F. Molecules 2004, 9, 109-116.
- [33]. Straub, A.; Stasch, J.; Alonso-Alija, C.; Benet-Buchholz, J.; Ducke, B.; Feurer, A.; Furstner, C. *Bioorg. Med. Chem.* 2001, 11, 781-784.
- [34]. Ge, M.; Cline, E.; Yang, L. Tetrahedron Lett. 2006, 47, 5797-5799.
- [35] Martins, M. A. P.; Cunico, W.; Siqueira, G. M.; Leidens, V. L.; Zanatta, N.; Bonacorso, H. G.; Flores, A. F. C. J. Braz. Chem. Soc. 2005, 16, 275-279.
- [36]. Martins, M. A. B.; Beck, P.; Machado, P.; Brondani, S.; Moura, S.; Zanatta, N.; Bonacorso, H. G. B.; Flores, A. F. C. *J. Braz. Chem. Soc.* 2006, *17*, 408-410.
- [37]. Atlan, V.; Buron, C.; Kaim, L. E. Synlett **2000**, *4*, 489-490.
- [38]. Soleiman, H. A.; Khalafallah, A. K.; Abd-Ellatif, H. Eur. J. Chem. 2012, 3(3), 316-321.
- [39]. Mohanty, M. K.; Sridhar, R.; Padmanavan, S. Y. Indian. J. Chem. 1977, 158, 1146-1148.